Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96EK9
UPID:
KTI12_HUMAN
Alternative names:
-
Alternative UPACC:
Q96EK9
Background:
Protein KTI12 homolog plays a crucial role in cellular processes, although its specific functions are yet to be fully elucidated. This protein, encoded by the gene with the accession number Q96EK9, is a subject of intense research due to its potential implications in various biological pathways.
Therapeutic significance:
Understanding the role of Protein KTI12 homolog could open doors to potential therapeutic strategies. Its involvement in key cellular mechanisms suggests that further research could unveil novel targets for drug discovery, contributing to the development of treatments for diseases currently lacking effective therapies.